An isoflavonoid derived from soy products. It inhibits protein-tyrosine kinase and topoisomerase-II (DNA topoisomerases, type II) activity and is used as an antineoplastic and antitumor agent. Experimentally, it has been... Experimentally, it has been shown to induce G2 phase arrest in human and murine cell lines.
- Mechanism
- Curator reviewed · 2 references
Genistein may inhibit cancer cell growth by blocking enzymes required for cell growth.
Genistein may decrease cardiovascular risk in postmenopausal women by interacting with the nuclear estrogen receptors to alter the transcription of cell specific genes. In randomized clinical trials, genistein was seen to increase the ratio of nitric oxide to endothelin and improved flow-mediated endothelium dependent vasodilation in healthy postmenopausal women. In addition, genistein may have beneficial effects on glucose metabolism by inhibiting islet tyrosine kinase activity as well as insulin release dependent on glucose and sulfonylurea.
- Primary indication
- Currently Genistein is being studied in clinical trials as a treatment for prostate cancer.Curator reviewed · 8 structured indications
- Formula / weight
- C15H10O5 · 270.2369 g/mol (avg)
- Also known as
- 4H-1-BENZOPYRAN-4-ONE, 5,7-DIHYDROXY-3-(4-HYDROXYPHENYL)- · 5,7-dihydroxy-3-(4-hydroxyphenyl)-chromen-4-one · Genisteol · Genisterin
- Code names
- BIO-300 · FW-635I-2 · NPI-031L · NSC-36586 · SIPI-807-1
Resolves to
TZBJGXHYKVUXJN-UHFFFAOYSA-NSMILESOC1=CC=C(C=C1)C1=COC2=C(C(O)=CC(O)=C2)C1=OWhat you can answer from here — as of September 23, 2026
Which drugs share a target with Genistein, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account